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1. INTRODUCTION & PURPOSE 
This document details the statistical analyses that will be undertaken and the presentation that will be 
followed, as closely as possible, when analysing and reporting the main results from the CAP study (Cluster 
randomised trial of testing for prostate cancer). 
The purpose of the plan is to:  
1. Ensure that the analysis is appropriate for the aims of the trial, reflects good statistical practice, and 
that interpretation of a priori and post hoc analyses respectively is appropriate. 
2. Explain in detail how the data will be handled and analyzed to enable others to perform the analysis 
in the event of sickness or other absence 
 
Additional exploratory or auxiliary analyses of data not specified in the protocol are permitted but fall 
outside the scope of this analysis plan. Such analyses would be expected to follow Good Statistical Practice. 
The analysis strategy will be made available if required by journal editors or referees when the main 
papers are submitted for publication.  Additional analyses suggested by reviewers or editors will, if considered 
appropriate, be performed in accordance with the Analysis Plan, but if reported the source of such a post-hoc 
analysis will be declared. 
Amendments to the statistical analysis plan will be described and justified in the final report of the trial. 
 
 
2. SYNOPSIS OF STUDY DESIGN AND PROCEDURES 
The information in this section is extracted from the study protocol (version 7, 29 May 2012) with the single 
purpose of ensuring an informed statistical analysis. For all other purposes reference MUST be made to the 
current version of the protocol. 
2.1. Trial aims and objectives 
To evaluate the effectiveness and cost-effectiveness of population screening for prostate cancer by 
establishing a cluster randomised trial allocating general practices to either intensive case-finding (the ProtecT 
trial) or unscreened standard practice. 
The objectives are: 
1) To provide an unbiased estimate of the effect of a single screen for prostate cancer on prostate cancer-
specific and all-cause mortality in the population. 
2) To contribute to the international effort to investigate the impact of prostate cancer screening. 
3) To estimate the cost implications of prostate cancer screening and use the data collected to develop and 
refine a probabilistic model of the cost-effectiveness of prostate cancer screening in the UK. 
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2.2. Trial design and configuration 
 
 
2.3. Trial centres 
Sheffield, Newcastle, Bristol, Cardiff, Birmingham, Leicester, Cambridge, Leeds. 
2.4. Eligibility criteria 
2.4.1. Inclusion criteria 
Men aged 50 to 69 years, registered at a participating GP practice. All GP practices in the study areas are 
eligible to participate, and are included in the random allocation. 
2.4.2. Exclusion criteria 
Men identified as already having a prostate cancer diagnosis on or before the date on which the list of men is 
generated for a practice. Men excluded by the study consent process (see protocol). 
2.5. Description of interventions 
The intervention is an invitation to PSA testing at a dedicated prostate cancer check clinic at or near the man’s 
GP practice. Those men found to have a high PSA level are invited to undergo a diagnostic biopsy. Those men 
found to have clinically localised prostate cancer are invited to have their treatment randomised in the ProtecT 
trial of surgery, radiotherapy, and conservative management. 
 
The comparison is standard NHS practice; GPs discuss the risks and potential benefits with those men 
requesting a PSA test. 
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2.6. Randomisation procedures 
The CaP study is cluster randomised. At each study centre, neighbouring groups of eight to twelve GP practices 
are block-randomised in a 1:1 ratio to PSA testing as part of the ProtecT study, or to NHS usual care in the 
comparison arm. When the group includes an odd number of practices, the greater number are allocated to 
the intervention arm. This randomisation is done by an independent statistician (S Brookes) with no other 
involvement with the study. The randomisation precedes approaches to the GP practices; practices are invited 
to participate in the arm of the study they are allocated to.  
 
Allocation is based on random numbers generated using the contemporary version of Stata statistical software 
(College Station, TX, USA). 
2.8. Blinding 
Members of the cause of death committee see patient vignettes, prepared to obscure the study arm the 
patient is in. Hence decisions about the cause of death are made blind to study arm.  
2.9. Trial committees 
The CaP study has a Data Monitoring Committee (DMC), chairperson Professor Lars Holmberg, which meets 
annually.  The chairperson for the CaP study Cause of Death Committee is Professor Peter Albertsen. 
2.10. Outcome measures 
2.10.1. Primary outcome 
The primary outcome is prostate cancer mortality at a median ten years after start of follow up.  
This includes those deaths judged as definitely or probably due to prostate cancer by the cause of death 
committee. Deaths due to the treatment of prostate cancer are included, again as judged by the cause of 
death committee. “Ten years” is the point in time when the median follow-up period for men in the study is 
ten years, which is anticipated to be the end of March 2016. Allowing a four month period for information on 
outcome events to reach us from the UK National Statistics Office, we propose to include all primary outcome 
events which have occurred on or before the 31st March 2016, and which we have received notification of by 
the 31st July 2016. Only outcome events for which we receive notification from the UK National Statistics Office 
will be included in the main analyses. 
2.10.2. Secondary outcomes 
1) All-cause mortality at 5,10 and 15 years after start of follow up 
2) Definite or probable prostate cancer mortality at 5 and 15 years  
3) Disease stage and grade at diagnosis  
4) Cost-effectiveness 
5) Health related Quality of Life 
Health related Quality of Life has been examined in separate sub-studies, and will not be considered further in 
this analysis plan. Similarly, cost-effectiveness will be the subject of a separate plan. 
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2.11. Interim analysis 
Interim analyses by trial arm will be conducted when requested by the DMC. These are prepared by the study 
DMC statistician (C Metcalfe) and shared only with the DMC in the first instance. There are no pre-defined 
formal stopping rules. 
 
3. GENERAL ANALYSIS CONSIDERATIONS 
3.1. Analysis populations 
The primary analysis set is all men aged 50 to 69 years registered with a participating practice on the date 
when the patient list is retrieved (the “list date”). Men are excluded as described in Section 2.4.2. 
 
3.2. Derived variables 
 
The primary outcome measure is a binary variable, distinguishing those individuals who definitely or probably 
died of prostate cancer, or treatment for prostate cancer. Time zero is the list date for the man’s GP practice. 
Failure time, or censoring time, is the date on which a man dies, on which the man has left the country, or the 
dataset closure date. 
3.3. Procedures for missing data 
Dates missing the day will be imputed as the 15th of the month. 
 
There will be no further imputation of missing data in the primary analysis of clinical effectiveness.  
3.4. Study centre effects 
The primary analysis is adjusted for randomisation cluster. This accommodates any between-centre 
differences in the outcome rate. In addition, differences in the intervention effect by study centre are 
examined as one of the pre-specified subgroup analyses (section 6.5 below). 
3.5. Competing risks 
As age is the only strong risk factor that prostate cancer mortality has in common with other causes of death, 
distortion of our results due to “competing risks” is unlikely. 
3.6. Clustering 
 
General practices are the unit of randomisation in this cluster randomised trial. Any variation between 
practices in the men’s outcome rates will be accommodated by separating that variation from that between 
individual men, using practice-level random effects. 
 
4. DESCRIPTION OF PARTICIPANT CHARACTERISTICS 
4.1. Disposition 
The recruitment of GP practices, and the flow of patients through the trial, will be summarised in a CONSORT 
diagram for cluster randomised trials (Campbell, 2004) that includes eligibility, reasons for exclusion, numbers 
randomised to the two intervention groups, losses to follow up and the numbers analysed. 
20160726_CAP_analysis_plan_1_5_signed.docx 
9 
 
4.2. Baseline characteristics 
The following comparisons are made between intervention and comparison arm practices, using data from 
routine primary care statistics: 
 Practice list size 
 IMD score (separately for England and Wales, lower level super output area) 
 Urban location 
 Prevalence of all cancer 
 Prevalence of diabetes 
 Prevalence of obesity 
 Prevalence of CHD 
Age on list date is the only baseline variable available for individual men. This is compared between the two 
arms of the study using a random effects model. 
 
5. ASSESSMENT OF STUDY QUALITY 
5.1. Eligibility checks 
Patients already diagnosed with prostate cancer on the list date are identified through cancer registry data. 
Details of men are removed from the study database as soon as we are aware of their active objection to being 
included in the study. Details of men who are excluded by our consent procedure (see protocol), are not 
transferred from the ProtecT to CaP databases.  
5.2. Data validation  
 
The primary outcome measure is validated by an independent cause of death committee.  
5.3. Study completion 
 
Follow up is passive from each participant’s point of view and consequently follow-up is completed for almost 
all men. One exception is men who emigrate; we censor follow-up for these men on the date when we 
become aware of them having emigrated.   
5.4. Compliance 
 
Data are being collected on those intervention arm men who undergo a PSA test as part of the study. 
 
5.5. Protocol deviations 
 
GP practices which do not agree to participate, having been randomised, are excluded from the study and 
analysis. 
 
In an effort to identify comparison arm practices who increase their PSA testing once recruited to the study, 
we will look at when prostate cancer diagnoses occur for each practice. A peak in diagnoses in the period after 
a comparison arm practice joins the study may indicate that practice has been prompted to increase the use of 
PSA testing.  
 
6. ANALYSIS OF EFFECTIVENESS 
6.1. Men who move GP practice 
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Patients are analysed according to the allocation of their GP practice. Duplicate records of men who have 
moved practices are removed; if the man moves between arms of the study, the record at the ProtecT practice 
is retained, otherwise the record collected at the earlier date is retained. The number of duplicates and the 
action taken is recorded. 
6.2. Summary of primary and secondary outcomes 
The combined endpoint “Definite, probable, and treatment-related prostate cancer mortality” will be 
summarised for each study arm as 5 and 10-year survival (estimated using the Kaplan-Meier method) with 95% 
confidence intervals. Nelson-Aalen cumulative hazard curves will be plotted in order to provide a graphical 
check of the proportional hazards assumption. If there is evidence of a difference between study arms, the 
number needed to invite (NNI; study question & policy context) in order to prevent one prostate cancer death 
will be calculated as one divided by the absolute difference in prostate cancer deaths between the randomised 
intervention and comparison groups. Following the ERSPC’s lead we will also present the number needed to 
detect (NND; with the assumption that these men are then treated), calculated as the NNI multiplied by the 
excess incidence of prostate cancer in the intervention group (Schroder 2009, 2014). In addition we will 
calculate the number needed to attend (NNA, corresponding to number needed to screen) calculated as one 
divided by the absolute difference in prostate cancer deaths between those men allocated to an invitation to a 
prostate check clinic and who attended, and those men in the comparison arm who would have attended had 
they been invited (this latter value will be estimated using the CACE approach described in section 6.4; Dunn, 
2002). The NNI, NNA and NND will be presented in the text of the main results paper. 
 
Similar statistics will be presented for prostate cancer mortality at other pre-specified time points, and for all-
cause mortality. 
 
Stage and grade at diagnosis will be presented as frequency tables, comparing the two arms of the study. 
6.3. Primary analysis 
The null hypothesis for the primary analysis is “no difference in definite, probable and treatment related 
prostate cancer mortality between men at GP practices inviting 50 to 69 year olds to a undergo a single PSA 
test, and men at GP practices following current NHS guidance”. The following Poisson regression model (1) 
incorporates the duration of follow-up for each man i by regressing rates λij on covariates where j is the man’s 
current age group. 
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Variation in outcome between randomisation strata r=1,…,R (neighbouring groups of GP practices) will be 
accommodated by standard deviation σr of a level 3, zero mean, normally distributed random effect y0r, and 
variation in outcome between GP practices p=1,…P will be accommodated as standard deviation σp  of a level 2 
zero mean normally distributed random effect. 
 
As the incidence of prostate cancer diagnosis varies greatly by age, each man’s follow-up will be divided into 
the following current age-groups according to a lexis-diagram approach: 59 years or younger, 60-64 years, 65-
69 years, 70-74 years, 75-79 years and 80 years or older. We will combine the 75-79 and 80+ age groups if 
there are too few events to permit separate analysis for the 80+ group. With a separate average baseline rate 
λ0j for each age group j, the assumption of a constant baseline rate will be reasonable for each separate age 
group separately. 
 
The treatment effect will be estimated as a rate ratio exp(β1), the coefficient for random allocation xi1 with 
value 0 for allocation to the comparison group and value 1 for allocation to the intervention group. 
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Our initial intention to further divide each man’s follow-up by current calendar period proved problematic for 
estimation in interim analyses for the DMC and so was abandoned. 
 
It is not anticipated that deaths due to other causes (“competing risks”) will be associated with prostate cancer 
disease, nor will the risk of their recurrence differ between intervention arms. Hence no special measures will 
be taken to account for competing risks. 
6.4. Secondary analyses 
The analysis in section 6.3 will be adapted to the analysis of other mortality measures. 
 
Analysis of the primary outcome will be repeated including (1) definite, probable, possible and treatment-
related prostate cancer mortality and (2) definite and treatment-related prostate cancer mortality. 
 
As has been done for the ERSPC study (Schroder 2009; Bokhurst 2013) statistical methods will be employed 
that use random allocation as an instrumental variable, to estimate the effect of the invitation to the prostate 
check clinic in those who accept the invitation and attend the prostate check clinic. In contrast to the ERSPC 
study, we will not attempt to control for contamination, due to the very strong assumptions required for this 
analysis (Metcalfe, 2013). Moreover we will not have data to indicate which men in the control arm have been 
screened for prostate cancer. 
We will employ a generalized method of moments estimator, which takes advantage of the random allocation 
as a strong instrumental variable, to compare those men in the intervention arm who attend the prostate 
check clinic, to the comparable men in the control arm who would attend the clinic if invited (Baum, 2013). 
Robust standard errors will be employed to accommodate any clustering of outcomes by GP practice. This 
analysis will employ Stata’s ivpoisson command, with the generalized method of moments estimator, 
multiplicative errors, and robust standard errors to allow for clustering: 
 
ivpoisson gmm pcadth (test = rand) [pw=w], 
 exp(exposure) mult vce(cluster practice_id) irr 
 
Where test indicates those men in the intervention group who attend the clinic, and rand indicates the 
randomly allocated arm. A key assumption underpinning this approach is that the subsequent rate of prostate 
cancer mortality is the same in the men who do not attend the clinic in the intervention arm and in those men 
in the comparison arm who would not have attended the clinic if invited (Metcalfe, 2013). 
 
The instrumental variable analyses described above will be done for all outcome measures in Table 2. 
 
6.5. Pre-specified sub-group analyses 
 
Sub-group analyses will examine whether the intervention effect varies by age group at baseline (50-54, 55-59, 
60-64, 65-69+ years), and by the index of multiple deprivation for a man’s area of residence (subgroups 
defined as tertiles for the cohort as a whole, but with Wales and England calculated separately)study centre. 
An interaction test p-value will be used to evaluate the evidence against the null hypothesis of equal 
intervention effect across sub-groups. If the association of outcome rate and age group is consistent with a 
linear trend, advantage will be taken of this to employ a single degree of freedom interaction test. 
6.6. Process analysis 
 
The analysis of age at diagnosis, stage and grade of prostate cancer will focus on men diagnosed with prostate 
cancer only. Mean age at diagnosis will be compared between study arms using ordinary linear regression. The 
proportions diagnosed over the ten-year average follow-up with Gleason scores of 6 or less, 7, and 8 or more, 
or diagnosed with clinical stage T1/T2 disease, clinical T3, and T4/N1/M1 stage disease grades 3+3, 3+4, 4+3, 
4+4, 4+5, 5+4 and 5+5 is will each be compared between study arms using ordered logistic regression. This 
approach is adapted to an analysis of disease stage, based on the TNM system. For this latter analysis the 
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patient is classified to the most advanced disease stage applicable from T1, T2, T3, T4, N1, M1. Robust 
standard errors will be employed to allow for variation between GP practices. 
 
6.7. Sensitivity analysis 
 
If imbalances between the participating practices allocated to each study arm are apparent, then prior to the 
primary analysis, the study PIs will list these characteristics, which will be added as further covariates in the 
regression model. Such analysis will be reported as a sensitivity analysis: the primary analysis will remain 
unchanged. 
Should any of the treatment arms in the ProtecT trial be shown to be superior (i.e. to lead to reduced 
mortality), then any difference in prostate cancer or all-cause mortality between intervention and comparison 
practices will be lower than would be expected if a screening programme had taken place when  the optimal 
treatment(s) were the standard of care. In this case we will estimate the beneficial effect on mortality of such 
an “optimal” screening programme, based on the (unbiased) treatment effect estimates from the ProtecT trial 
and the (unbiased) overall effect estimates from the CAP study.  
We will repeat the comparison of Gleason score at diagnosis of prostate cancer between the intervention and 
comparison groups, with the Gleason score reduced to a binary distinction between scores of 7 and below 
versus 8 and above. There is some evidence that whilst UK histopathologists have remained consistent in their 
use of the 7/8 distinction over the study period, they may have increased their use of a score of 7 rather than 6 
during that time (Oxley 2015). 
We will re-estimate the risk ratios estimated using the instrumental variable approach described in Section 6.4 
above under an alternative definition of the instrumented variable: attended the PCC clinic, had blood taken 
for a PSA test, and received a result which could be acted upon. 
We will recalculate the incidence of prostate cancer in the intervention arm, including those diagnoses we 
became aware of due to ProtecT diagnostic procedures, but of which we were not notified by the UK National 
Office of Statistics. 
As has been done for the ERSPC study (Schroder 2009; Bokhurst 2013) statistical methods are employed that 
use random allocation as an instrumental variable, to estimate the effect of testing in those who do undergo 
PSA testing (Palmer, 2011). This estimate can be used to predict the overall effect of a screening programme 
under different assumptions about PSA uptake. In contrast to the ERSPC study, we do not attempt to control 
for contamination, due to the very strong assumptions required for this analysis (Metcalfe, 2013). 
 
6.8. Scotland 
 
We are applying for anonymised data on men in intervention (ProtecT) and control practices in Scotland. These 
data will be for men fitting our eligibility criteria, and will include outcome data for a ten-year period. The key 
difference between these Scottish data and the data we are collecting for the CAP study in England and Wales 
is that it will not be possible to validate the cause of death for Scottish men; we will need to rely on the death 
certificates. Consequently, for the primary CAP analysis, we will analyse and present the data for Scottish men 
separately, but using the same statistical approach as described in the statistical analysis plan. If a case can be 
made for the Scottish data being of acceptable quality, then it will be included in a possible future meta-
analysis of data from the CAP and the ERSPC. 
 
 
7. CHANGES SINCE VERSION 1.4 
Substantive changes since the previous version have been highlighted in green. In summary these are: 
 On the advice of the Trial Steering Committee (January 2016, see Appendix 2), we will present the 
number needed to invite, the number needed to attend, and the number needed to detect as 
described in Section 6.2. 
 We previously planned to present an estimate of the effect of screening in those who attend the 
prostate check clinic in a sensitivity analysis. On the advice of the Trial Steering Committee (January 
20160726_CAP_analysis_plan_1_5_signed.docx 
13 
 
2016), we will now present such estimates for all the outcomes in Table 2 as secondary analyses. 
Consequently we have pre-specified these analyses in more detail in Section 6.4. Furthermore, we are 
now specific that the aim of these analyses is to estimate the effect of the intervention, an invitation 
to a prostate check clinic, in those men who attend the clinic. These estimates will be calculated using 
an instrumental variable approach, to avoid the known biases of the per protocol approach. 
 We now plan a sub-group analysis by area index of multiple deprivation, rather than by study centre, 
as described in Section 6.5. 
 We now make it clear that we are also interested in comparing age at prostate cancer diagnosis 
between the two study arms, as described in Section 6.6. We have added a sensitivity analysis looking 
at the proportion of men diagnosed with Gleason score of 8, compared between the intervention and 
comparison groups, to avoid confounding by “Gleason drift”. 
 Outlines of the Figures and Tables to be included in the primary results paper are given in the 
Appendix. 
 
In addition there have been minor amendments to grammar. 
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APPENDIX 1 
 
Figure 1. CONSORT diagram for recruitment into the Cluster Randomised Trial of Testing 
for Prostate Cancer (CAP), England and Wales. 
 
 
Figure 2a. Incidence of prostate cancer Cumulative incidence of prostate cancer in the 
intervention (solid line) compared to control (long dash line) groups 
 
Figure 2b. Primary analysis Cumulative incidence of definite and probable prostate cancer 
and intervention related mortality in the intervention (solid line) compared to control (long 
dash line) groups 
 
Figure 2c All-cause mortality Cumulative incidence of all deaths in the intervention (solid 
line) compared to control (long dash line) groups 
 
Figure 2d Secondary analysis Cumulative incidence of definite, probable and possible 
prostate cancer and intervention related mortality in the intervention (solid line) compared to 
control (long dash line) groups 
 
 
 
 
 
 
 
  
20160726_CAP_analysis_plan_1_5_signed.docx 
16 
 
 
Table 1. Characteristics of prostate cancer cases at the time of diagnosis 
 
 
  
Intervention arm 
 Control arm 
 
n = 
Intervention arm 
 
n= 
Attended 
prostate check 
clinic 
n = 
Did not attend 
prostate check 
clinic 
n = 
     
Mean age at diagnosis 
(standard deviation) 
    
     
Grade at diagnosis (%)*     
≤6     
7     
≥8     
Missing     
     
Stage at diagnosis (%)*     
T1/T2  
(stage I/stage II)  
 
    
T3 (stage III)     
T4/ M1/N1 (stage IV)     
Missing     
 
*Column percentage of diagnosed men in the indicated group and who have data recorded for this 
variable. 
 
 
Table 2. Prostate cancer specific mortality and all-cause mortality by random allocation: intention-to-screen estimate and instrumental variable estimate of the 
effect of screening in men allocated to and attending the prostate check clinic 
  
 
 
Intervention arm 
 
 
 
Control arm 
    Effect of screening 
amongst those 
attending clinic 
(N=xxx,xxx) 
 Deaths Rate per 1000 
person year 
(95% CI) 
Deaths Rate per 1000   
person year 
(95% CI) 
Rate 
Difference 
(95% CI) 
 Rate ratio  
(95% CI) 
p-value1 Rate ratio 
(95% CI) 
p-value 
Primary Outcome           
Definite or probable prostate 
cancer death or IRD 
          
Secondary Outcomes           
All-cause mortality           
Definite or probable or possible 
prostate cancer death or IRD 
          
Definite prostate cancer death 
or IRD 
          
CI denotes confidence interval; IRD = intervention related death 
1. Likelihood ratio test of the null hypothesis “no difference in prostate cancer mortality between the arms”, adjusted for current age 
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Table 3. Planned sub group analyses of prostate cancer specific mortality1 
 Intervention arm Control arm     
 Deaths  Rate per 1000 
person year 
(95% CI) 
Deaths  Rate per 1000   
person year 
(95% CI) 
Rate 
difference 
(95% CI) 
  Rate 
Ratio 
(95% CI) 
p-value1 
Age at baseline         
50-54         
55-59         
60-64         
65-69+         
         
IMD area deprivation England       
Tertile 1         
Tertile 2         
Tertile 3         
IMD area deprivation Wales        
Tertile 1         
Tertile 2         
Tertile 3         
1.  Definitely or probably due to prostate cancer or intervention related death, as established by the Independent Cause of Death Evaluation Committee 
2. Likelihood ratio interaction test of the null hypothesis of no difference in the comparison across the different subgroups 
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SUPPLEMENTARY MATERIAL 
 
 
Supplementary Table S1. Individual and practice level characteristics at baseline 
 Intervention arm 
 
Control arm 
 
Individual Characteristics n= xxx,xxx men n= xxx,xxx men 
Mean age (s.d.)   
Mean IMD score England (s.d.)   
Mean IMD score Wales (s.d.)   
Urban/rural (%)**   
   
Practice Characteristics n= xxx practices n= xxx practices 
Mean practice list size (s.d.)   
Number of urban practices (%)   
Number of single versus 
multiple partner GP practices 
(%)*** 
  
Number of teaching practices 
(%)*** 
  
Mean QOF score (s.d.)***   
Mean IMD score in England 
(s.d.) 
  
Mean IMD score in Wales 
(s.d.) 
  
Mean prevalence from QOF   
All cancers (s.e)   
Diabetes (s.e)   
Obesity (s.e)   
Coronary heart disease (s.e)   
s.d. = standard deviation; s.e. = standard error; *if we can obtain reliable data from HSCIC, not 
currently in request for whole cohort; **if we obtain reliable data from the HSCIC, ***if we obtain 
reliable data from QOF 
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APPENDIX 2 
Signed extract from the Trial Steering Committee 
 
 
 
 
